Pieris

2015 gelang dem Portfoliounternehmen Pieris der Börsengang an der NASDAQ. Eine Pressemitteilung des Unternehmens dazu finden Sie  hier. 

Pieris Pharmaceuticals, Inc. is a public clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that may help patients suffering from cancer, asthma, anemia and other medical conditions with a high unmet medical need.

Pieris has a diverse pipeline of Anticalin® therapeutics and has R&D collaborations with several partners.